IPM Take
Europe’s oncology market is changing shape.
The European Commission’s approval of serplulimab in first-line squamous non-small cell lung cancer is not just another PD-1 decision. It is another sign that China-origin cancer innovation is no longer waiting at the edge of Western markets. The science is travelling. The real question is whether European reimbursement systems will let patients follow.
Executive Summary
Shanghai Henlius announced that the European Commission approved serplulimab, marketed in Europe as Hetronifly, in combination with chemotherapy for the first-line treatment of adults with unresectable locally advanced or metastatic squamous non-small cell lung cancer.
The decision is supported by ASTRUM-004, a randomised, double-blind international Phase III trial of serplulimab plus chemotherapy in previously untreated advanced squamous NSCLC. The study reported improvements in overall survival and progression-free survival compared with chemotherapy alone.
Henlius has previously obtained European approvals for serplulimab in extensive-stage small-cell lung cancer, non-squamous NSCLC and oesophageal squamous cell carcinoma. The company reports that the product has already been launched in several European markets, but country-level reimbursement and treatment-pathway decisions remain decisive for access to the new indication.
Why it matters
- Patients / advocates: A new first-line option matters only if it reaches clinics before disease progression narrows the pathway.
- Clinicians: Squamous NSCLC treatment choices continue to expand, increasing the need for clear sequencing and local prescribing pathways.
- Payers: European authorisation does not remove country-level decisions on reimbursement, value and implementation.
- Regulators: The decision confirms that global oncology development is no longer flowing in one direction.
For a patient with metastatic lung cancer, geopolitics is not the first thing on their mind.
They want to know whether the treatment is available. Whether it is funded. Whether the oncologist can prescribe it now, not after another committee meeting or another reimbursement delay.
That is why the European Commission’s approval of serplulimab plus chemotherapy in first-line squamous NSCLC matters beyond the regulatory headline.
Henlius is a Shanghai-based biotech. Its anti-PD-1 therapy was developed through a global clinical programme and has now secured a fourth European indication. That makes the story bigger than one product. It reflects a changing oncology map, where China-origin medicines are increasingly moving through European regulatory channels and into highly competitive treatment markets.
The clinical evidence is already established. ASTRUM-004 showed that serplulimab plus chemotherapy improved key survival outcomes in previously untreated advanced squamous NSCLC compared with chemotherapy alone. The Commission’s decision turns that evidence into a legal treatment option across the European Union and European Economic Area.
But authorisation is the easy part.
The hard part is access. Europe still has many oncology markets, not one. Reimbursement decisions, formularies, hospital budgets and treatment protocols remain national or local. A therapy can be approved in Brussels and remain out of reach in a hospital a few hundred kilometres away.
That gap matters in squamous NSCLC, where patients often arrive with advanced disease and limited time for administrative delay. The difference between a regulatory approval and a funded pathway is not bureaucratic. It can become clinical.
For IPM, this is the sharp political point. Innovation is global. Access is still fragmented.
Europe has opened another lung cancer door. National systems now have to decide whether patients can actually walk through it.
